Legislative and regulatory proposals to change international and domestic corporate tax law and policy, including reconciliation legislation. Funding for Hepatitis C, HIV, oncology, and public health activities via appropriations. Advocate on drug pricing proposals, including reconciliation legislation. Issues related to pharmaceuticals and intellectual property protection including technology transfer, patent rights and funding. Advocate on drug pricing proposals, including reconciliation legislation. HCV testing, screening and linkage to care programs. Medicaid and Medicare coverage, access and reimbursement issues for Hepatitis C, HIV, oncology products, and COVID-19 therapies including Medicare Part B proposals, and Medicare Part D reform and benefit redesign. CMS rules related to Notice of Benefit and Payment Parameters (NBPP), hospital inpatient payments, and Value-Based Purchasing arrangements including changes to best price. Advocate on drug pricing proposals, including reconciliation legislation, and expanding access to HIV treatment and prevention therapies including: Ryan White Care Act reauthorization; PEPFAR reauthorization; HIV/AIDS access to care, research, testing and treatment. Hepatitis C screening and linkage to care programs; coverage and reimbursement policy for Hepatitis C, HIV and oncology portfolio. Issues related to triple negative breast cancer (TNBC) and early detection and screenings for breast cancer. Engage on pharmaceutical policy as it relates to payments under the 340B program. Highlight Gilead's efforts to ensure diversity in clinical trials. Issues related to developing treatments for COVID-19 (2019 Novel Coronavirus), including: manufacturing, clinical trials, reimbursement and coverage of Veklury (remdesivir). Reauthorization of the Prescription Drug User Fee Act and related issues. International trade and protection of intellectual property; TRIPS Waiver; compulsory licensing and other IP issues in multiple countries.
TAX - Taxation/Internal Revenue Code BUD - Budget/Appropriations CPT - Copyright/Patent/Trademark MMM - Medicare/Medicaid HCR - Health Issues TRD - Trade (domestic/foreign)
24 - Commerce, Dept of (DOC) 2 - HOUSE OF REPRESENTATIVES 1 - SENATE 41 - Treasury, Dept of 2 - HOUSE OF REPRESENTATIVES 1 - SENATE 24 - Commerce, Dept of (DOC) 34 - Health & Human Services, Dept of (HHS) 2 - HOUSE OF REPRESENTATIVES 113 - Patent & Trademark Office (PTO) 1 - SENATE 22 - U.S. Trade Representative (USTR) 136 - Centers For Medicare and Medicaid Services (CMS) 34 - Health & Human Services, Dept of (HHS) 2 - HOUSE OF REPRESENTATIVES 18 - Office of Management & Budget (OMB) 1 - SENATE 12 - White House Office 134 - Centers For Disease Control & Prevention (CDC) 136 - Centers For Medicare and Medicaid Services (CMS) 24 - Commerce, Dept of (DOC) 135 - Food & Drug Administration (FDA) 34 - Health & Human Services, Dept of (HHS) 2 - HOUSE OF REPRESENTATIVES 139 - Natl Institutes of Health (NIH) 13 - Office of the Vice President of the United States 1 - SENATE 39 - State, Dept of (DOS) 22 - U.S. Trade Representative (USTR) 12 - White House Office 24 - Commerce, Dept of (DOC) 34 - Health & Human Services, Dept of (HHS) 2 - HOUSE OF REPRESENTATIVES 16 - Natl Security Council (NSC) 113 - Patent & Trademark Office (PTO) 1 - SENATE 39 - State, Dept of (DOS) 22 - U.S. Trade Representative (USTR)
GILEAD SCIENCES, INC.
333 LAKESIDE DRIVE, FOSTER CITY, CA, 94404, US
DAVID PULLIAM CHARLES M. CLAPTON TERESA BILL BILL BODE GRACE RODDEN JENNIFER NIETO CAREY CHARLES M. CLAPTON DAVID PULLIAM GRACE RODDEN BILL BODE JENNIFER NIETO CAREY CHARLES M. CLAPTON DAVID PULLIAM TERESA BILL BILL BODE GRACE RODDEN JENNIFER NIETO CAREY ANNA GRIFFIN MICHAEL D BOYD CHARLES M. CLAPTON DAVID PULLIAM TERESA BILL BILL BODE GRACE RODDEN JENNIFER NIETO CAREY ANNA GRIFFIN MICHAEL D BOYD CHARLES M. CLAPTON DAVID PULLIAM GRACE RODDEN MICHAEL D BOYD CHARLES M. CLAPTON DAVID PULLIAM